STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3574 by analyst upside · 2026-08-13
GRAL
GRAIL, Inc.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+5.0%
implied upside to consensus target
Current Price $68.94
Consensus Target $72.38
Bull Target $88.0
Bear Target $60.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
4
Sell
0
52-Week Low $29.95
52-Week High $118.84
YTD Return -22.4%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-8.85
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $165M
Profit Margin -236.9%
52-WEEK RANGE
52-Week Low $29.95
52-Week High $118.84
Current Price $68.94
Bear Target $60.0
Bull Target $88.0
● Now $68.94 ● Target $72.38
TRADING DATA
Avg Volume 709K
YTD Return -22.4%
Analyst Count 8
Consensus Buy
Upside to Target +5.0%
Last Updated 2026-08-13

ANALYST SUMMARY

GRAIL, Inc. (GRAL) is currently trading at $68.94 with a Wall Street consensus price target of $72.38, implying potential upside of 5.0% over the next 12 months. 8 analysts currently cover GRAL, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $88.0, while the most cautious has a target of $60.0.

GRAL operates in the Healthcare sector with a market capitalisation of $3B. The stock is down 22.4% year-to-date and is currently trading near the lower end of its 52-week range of $29.95 – $118.84.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for GRAL, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Goldman Sachs ● Initiated
Neutral 2026-06-05 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-05-06 Building track record
Piper Sandler - Reiterated
Neutral → Neutral 2026-05-06 14% win rate (7 calls)
Mizuho ● Initiated
Neutral 2026-04-10 Building track record
Piper Sandler ● Initiated
Neutral 2026-04-10 14% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-03-30 62% win rate (8 calls)
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-02-24 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-02-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
17/30
Consensus clarity
22/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →